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Abstract: The purpose of this study was to conduct a literature review of cost-benefit 
studies on pharmacotherapy and psychotherapy treatments of alcohol dependence (AD).  
A  literature  search  was  performed  in  multiple  electronic  bibliographic  databases.  The 
search identified seven psychotherapy studies from the USA and two pharmacotherapy 
studies from Europe. In the psychotherapy studies, major benefits are typically seen within 
the  first  six  months  of  treatment.  The  benefit-cost  ratio  ranged  from  1.89  to  39.0. 
Treatment with acamprosate was found to accrue a net benefit of 21,301 BEF (528 €) per 
patient over a 24-month period in Belgium and lifetime benefit for each patient in Spain was 
estimated to be Pta. 3,914,680 (23,528 €). To  date, only  a few studies exist that have 
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examined the cost-benefit of psychotherapy or pharmacotherapy treatment of AD. Most of 
the available treatment options for AD appear to produce marked economic benefits. 
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1. Introduction 
There are many types of treatment for alcohol dependence (AD), including psychosocial support 
groups such as Alcoholics Anonymous, inpatient and outpatient treatment, psychological interventions, 
pharmacological treatment, employee assistance programs (EAPs) and most typically, a combination 
of  the  aforementioned  [1,2].  Most  psychosocial  interventions  (e.g.,  cognitive  behavioural  therapy, 
motivational enhancement therapy) focus on helping patients decrease the frequency of alcohol use, 
and also address issues that have maintained their drinking behaviours such as familial, social, and 
work-related  dynamics  [3-5].  Psychosocial  intervention  formats  are  either  one-on-one  individual 
counselling or group counseling. 
Pertaining to pharmacotherapies, the U.S. Food and Drug Administration (FDA) has approved four 
pharmacologic  agents  for  the  treatment  of  AD  to  date:  disulfiram,  oral  naltrexone,  injectable  
long-acting  naltrexone,  and  acamprosate.  The  European  Medicines  Agency  has  not  yet  approved  
long-acting naltrexone.  
Disulfiram, an aversive agent, has been used to treat AD for more than 50 years; however, the 
evidence for its effectiveness is weak. It has significant adverse effects and there is not sufficient 
evidence that it increases abstinence rates, decreases relapse rates, or reduces cravings [6]. Per the 
FDA, oral Naltrexone is indicated in the treatment of AD in combination with an appropriate plan of 
management for alcohol addiction. Over 20 clinical trials, as well as meta-analytic reviews support a 
modest effect of oral naltrexone, and support its effect on reducing heavy drinking, increasing abstinence 
rates  and  decreasing  alcohol  cravings  in  a  number  of  study  populations  (e.g.,  [7-9]).  Long-acting 
injectable naltrexone is indicated for the treatment of AD in conjunction with psychosocial support for 
patients who are abstinent at treatment initiation. Reductions in the number of drinking days and heavy 
drinking days have been reported; similar to oral Naltrexone, the effects are small [10]. 
In  contrast  to  naltrexone,  acamprosate  is  indicated  for  the  maintenance  of  abstinence  from  
alcohol in patients who are abstinent from consuming alcohol and who are simultaneously engaged  
in psychosocial support. Recent reviews of acamprosate in clinical trials suggest that the medication  
is  primarily  effective  in  extending  continuous  abstinence  (e.g.,  [8,11]).  Some  other  medications, 
although not approved by the U.S. FDA for the treatment of AD, have some support for their efficacy, 
such  as  anticonvulsants  (e.g.,  gabapentin,  topiramate  [12],  baclofen  [13],),  serotonergic  agents  
(e.g., sertraline [14,15], ondansetron [12]), and glutamatergic agents (e.g., mementine; [6,16]). 
To date, there are only a few studies that have examined the costs/benefits of psychotherapy or 
pharmacotherapy treatment of AD (see for example, [17]). A Cost-Benefit Analysis (CBA) incorporates 
multiple outcome measures to gain a more comprehensive picture of the total economic impact of the 
AD treatment. This analysis allows valuing of all outcomes of treatment in monetary terms so that the 
net  economic  benefits  or  a  benefit-cost  ratio,  both  of  which  enable  the  comparison  of  different Int. J. Environ. Res. Public Health 2011, 8                 
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treatment options, can be obtained. The purpose of the current study was to conduct a search of the 
current  literature  in  order  to  determine  the  available  evidence  of  cost-benefit  analyses  on 
pharmacotherapy and psychotherapy AD treatments.  
2. Materials and Methods 
2.1. Literature Search 
A literature search for studies that have conducted a CBA on the social costs/benefits attributable to 
AD  treatment  was  performed  in  multiple  electronic  bibliographic  databases  from  January  1995  to 
January 2011, including: Ovid MEDLINE, PubMed, EMBASE, Web of Science, and PsychINFO. 
Google  Scholar,  the  Cochrane  Database  of  Systematic  Reviews  and  economic  databases,  such  as 
Centre for Review and Dissemination (CRD) (http://www.crd.york.ac.uk/crdweb/) were also searched. 
The search was conducted using multiple combinations of the following key words: alcohol, alcoholism, 
cost,  dependence,  treatment,  pharmacotherapy,  psychotherapy,  psychosocial  treatment,  cost-benefit 
analysis, and economic evaluation. The search was not limited to English language publications or to 
any geographic area. 
2.2. Data Extraction  
Three investigators (S.M., J.P., and S.P.) independently extracted information from the identified 
studies. Training of coders to achieve sufficient (>0.80) interrater reliability (IRR) was conducted. 
IRR, a statistical measure for the degree of agreement among raters that gives a score of how much 
homogeneity, or consensus there is in the ratings given by different raters, was calculated by Fleiss’ 
kappa statistics using the attribute agreement analytic method. Discrepancies were reconciled by a 
fourth investigator (JR) independent of the first process. All analyses related to IRR were computed 
using Minitab  statistical software [18]. Using a standardized spreadsheet (MS-Excel), each study 
was coded for the following variables: reference, country where the study was completed, sample size, 
type of intervention, types of cost, types of benefits, and benefit-cost ratio. 
3. Results 
In total, 94 articles were identified. After reviewing these articles, 61 articles were retained that 
included economic evaluations of alcohol treatment. Upon further screening for studies involving CBA 
of  AD  treatment,  the  data  were  extracted  from  nine  articles  providing  original  studies  on  the  
cost-benefit  of  AD  treatment:  seven  psychotherapy  studies  from  USA  and  two  pharmacotherapy 
studies  from  Europe  (one  each  from  Belgium  and  Spain).  A  flow  diagram  describing  the  search 
strategy is presented in Figure 1. Int. J. Environ. Res. Public Health 2011, 8                 
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Figure 1. Flow diagram describing the search strategy for cost-benefit studies of alcohol 
dependence treatment. 
 
 
There was a high IRR (j = 0.81, P < 0.0001) among the three reviewers across all variables coded. 
Table 1 provides the type of intervention and  cost descriptions for the identified studies. The net 
benefits and/or benefit-cost ratios are presented in Table 2. 
94 Computer assisted + manual search 
Key words: alcohol, alcoholism, cost, dependence, treatment, 
pharmacotherapy, psychotherapy, psychosocial treatment, cost-benefit 
analysis, and economic evaluation.  
33 articles excluded from the 
study: no data on economic 
evaluation of AD treatment 
38 articles excluded from the 
study: not involving cost-benefit 
analysis of AD treatment 
23 studies selected for review 
13 articles excluded from the study: 
not involving original cost-benefit 
analysis of AD treatment 
9 studies selected for data extraction: 
7 Psychotherapy studies 
2 Pharmacotherapy studies 
61 studies identified for further screening 
for cost-benefit analysis of AD treatment 
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Table 1. Summary of cost-benefit studies on alcohol dependence treatment. 
Reference  Country  Population & Sample Size  Type of Intervention  Type of Cost 
PSYCHOTHERAPY 
[19]  USA 
36 newly abstinent married  
male alcoholics 
1. IC  
2. IC + BMT  
3. IC + ICT & 24 month follow-up 
Average costs:  
IC $450;  
IC + BMT $857 
IC + ICT $895 
[20]  USA 
59 couples with a newly 
abstinent alcoholic husband 
1. BMT  
2. BMT + RP 
Average costs:  
BMT $864,  
BMT + RP $1,640 
[21]  USA  482 M & 292 W, age 18–65 
BI by physicians & 12 month follow-up; 
Review of the prevalence of problem drinking, 
PT specific alcohol effects, worksheet on 
drinking cues, drinking agreement as a 
prescription & drinking diary cards 
$205 per PT 
(clinic cost $165.65, PT cost 
$38.97) 
[22]  USA  482 M & 292 W, age 18–65 
BI by physicians & 48 month follow-up;  
Review of normative drinking, PT specific 
alcohol effects, worksheet on drinking cues, 
drinking diary cards, drinking agreement as a 
prescription 
$205 per PT  
(clinic cost $166, PT cost 
$39) 
[23]  USA  105 M & 53 W, age 65+ 
Brief intervention by physicians & 24-month 
follow-up assessment, feedback, contracting  
& goal-setting 
$236 per PT 
(clinic cost $197, PT cost 
$39) Int. J. Environ. Res. Public Health 2011, 8                 
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Table 1. Cont. 
Reference  Country  Population & Sample Size  Type of Intervention  Type of Cost 
[24]  USA  Primary care clinics   BI by physicians: 12- & 48-month follow-up 
$205 per PT  
(Screening & assessment 
$88, training cost $23, 
intervention cost $55, PT 
cost $39) 
[25]  USA 
Injured PT treated in an 
emergency department or 
admitted to a hospital (6%  
of 20,507,601 adult PTs  
treated for injuries) 
Screening + BI 
Direct injury-related medical 
costs (screening + BI) $600 
per PT  
PHARMACOTHERAPY 
[26]  Belgium  448 alcoholic PT 
12-month treatment with acamprosate &  
12-month follow-up 
Per-PT cost:  
No treatment 5,783 €; 
Acamprosate 5,255 € 
[27]  Spain 
Total alcohol-dependent PT 
population in Spain 
(approximately 627,400)  
Treatment with acamprosate for 1 year,  
time horizon for benefit was 11–16 years 
Spain Pta 42,430 million per 
year if 50% of affected PT 
received treatment  
(Pta 33,944 million if 40% 
received treatment &  
Pta 50,917 million if 60% 
received treatment) 
BI: Brief Intervention; BMT: Behavioural Marital Therapy; IC: Individual Counselling; ICT: Interactional Couples Therapy: PT: Patient(s);  
RP: Relapse Prevention; M: Men; W: Women. Int. J. Environ. Res. Public Health 2011, 8                 
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Table 2. Net benefit or cost-benefit ratio for alcohol dependence treatment. 
Reference  Country  Net Benefits  Benefit-cost Ratio 
PSYCHOTHERAPY 
[19]  USA  Average benefits: IC, $7,581;  
IC + BMT, $6,681;  
IC + ICT, (−)$2,248 
IC, 20.77  
IC + BMT, 8.64  
IC + ICT, (−)$2.82 
[20]  USA  Average benefits: BMT, $5,053; 
BMT + RP, $3,365 
BMT, 5.97,  
BMT + RP, 1.89 
[21]  USA  $1,151 per PT  
Savings: Medical $523, Legal cost & MVE $629 
3.2 Medical,  
5.6 Societal 
[22]  USA  $7,985 per PT  
Savings: Medical $712, Legal cost $102, MVE $7,171 
4.3 Medical,  
39.0 Societal 
[23]  USA  $5,241 per PT  
Savings: Medical $3,260, MVE $1,613, Life-years lost $368,  
Other social consequences $1,981 
NA 
[24]  USA  $7,985 per PT  
Savings: Medical $712, Legal cost $102, MVE $7,171 
4.3 Medical,  
39.0 Societal 
[25]  USA  $89 for each PT screened; $330 for each PT offered BI  3.81 Medical 
PHARMACOTHERAPY 
[26]  Belgium  Per PT acamprosate-attributable net cost-savings:  
€ 528 over 2 years 
NA 
[27]  Spain  Lifetime benefit for each PT, Pta 3,914,680;  
avoidance of indirect costs & nonspecific direct costs, Pta 
3,409,349; avoidance of direct health-related benefits, Pta 505,331 
NA 
BI: Brief Intervention; BMT: Behavioural Marital Therapy; IC: Individual Counselling; ICT: Interactional 
Couples Therapy; MVE: Motor Vehicle Event; NA: Not Available; PT: Patient(s); RP: Relapse Prevention. 
3.1. Psychotherapy Studies 
In a study in Massachusetts, USA [20] involving 36 newly abstinent married male alcoholics, the 
patients were divided into three groups for outpatient treatment, namely: (1) Individual counselling;  
(2) Individual counselling plus behavioural marital therapy (BMT); and (3) Individual counselling plus 
interactional couples therapy (ICT) with a 24-month follow-up. It was observed that both individual 
counselling alone and in combination with BMT showed substantial and significant cost savings from 
reduced utilization of healthcare and legal systems that substantially and significantly exceeded the 
cost of delivering the treatment. Individual counselling alone had a higher benefit-cost ratio (20.77) 
than  BMT  plus  individual  counselling  (8.64)  due  to  the  lower  cost  of  delivering  the  treatment. 
Individual  counselling  plus  ICT  had  a  negative  benefit-cost  ratio  of  (−2.82)  due  to  the  high  cost  
of treatment.  
Another  study  by  the  above  research  group  [20]  involving  59  couples  with  a  newly  abstinent 
alcoholic husband, estimated the cost-benefit of BMT with or without relapse prevention (RP) sessions 
for alcoholics and their spouses. Both standard BMT and for the longer and more costly form of BMT 
with the additional RP sessions showed (a) decreases in health care and legal costs after, as compared 
to before, treatment; (b) positive cost offsets (or savings); and (c) benefit-cost ratios greater than 1, 
indicating that health and legal system cost savings (i.e., benefits) exceeded the costs of delivering the Int. J. Environ. Res. Public Health 2011, 8                 
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BMT treatments. In fact, cost savings from reduced utilization were more than 5 times greater than the 
cost of delivering the standard 5- to 6-month BMT program. Although adding RP to BMT led to less 
drinking and better marital adjustment, it did not lead to greater cost savings in health and legal service 
utilization. The benefit-cost ratio for BMT was 5.97 compared to 1.89 for BMT with RP. 
Two cost-benefit analyses [21,22] involving brief interventions by physicians through review of the 
prevalence of problem drinking, patient specific alcohol effects, worksheet on drinking cues, drinking 
agreement in the form of a prescription and drinking diary cards for 482 men and 292 women (age  
18–65) in Wisconsin, USA, exhibited positive net benefits for patients, the healthcare system as well 
as society. The intervention, conducted by physicians, included two 15-minute face-to-face counselling 
sessions one month apart and two 5-minute nurse follow-up phone contacts. The average number of 
drinks and binge drinking episodes declined at the 6-month follow-up point. Although it declined 
further during 12–48 month follow-up, the major effect occurred within six months of the intervention. 
The benefit-cost analysis was performed from two different perspectives: (1) the medical care system 
perspective, which considered costs to the medical care system and benefits from reductions in future 
emergency room visits and hospitalizations; and (2) the societal perspective, which considered all costs 
and benefits to the clinic, patient, and society in general. The benefit-cost ratios were 3.2 and 4.3 for 
the medical system, and the societal benefit-cost ratios were 5.6 and 39.0 after 12 and 48 months of 
treatment, respectively. 
Mundt and colleagues [23] examined older adults (105 men and 53 women, aged 65 and older) who 
received a brief intervention by a physician through assessment, feedback, contracting and goal setting. 
Results indicated a 40% decrease in average weekly alcohol consumption compared to 6% in the 
control group in 3-month follow-up and maintained significantly lower levels of alcohol consumption 
and heavy episodic drinking throughout a 24-month observation period. Monetary benefits of $5,241 
per patient ($3,260 in healthcare and motor vehicle events: $1,613, life-years lost: $368, and other 
social consequences: $1,981) were observed for the treatment group as compared to the control group.  
In a study of injured patients treated in an emergency department or admitted to a hospital in the 
USA, Gentilello and colleagues [25] analyzed direct injury-related medical costs and cost-benefits due 
to screening and brief intervention. It was found that if the brief intervention was offered, the expected 
cost of screening, intervention, and subsequent emergency department visits and hospital admissions 
over the next three years was $600 per patient. In the scenario where screening and intervention were 
not offered, the expected cost of subsequent emergency department visits and hospital admissions was 
$689 per patient over three years, resulting in an estimated cost savings of $89 per injured patient 
screened, or $330 for each patient offered a brief intervention. The brief intervention resulted in $3.81 
in health care costs saved for every $1.00 spent on screening and intervention. 
3.2. Pharmacotherapy Studies 
In a study [26] involving 448 alcoholic patients in Belgium, 12-month treatment with acamprosate 
and  12-month  follow-up  resulted  in  net  cost  savings  of  21,301  BEF  (528  €)  per  patient  over  a  
24-month period for acamprosate treatment compared to placebo (Figure 2), due to a fewer acute 
hospitalizations for detoxification, less liver complications and less institutionalized rehabilitation.  Int. J. Environ. Res. Public Health 2011, 8                 
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Figure  2.  Distribution  of  costs  (in  Euros)  for  acamprosate  versus  no  treatment  in  the 
Belgian study [26]. 
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It was estimated that treatment with acamprosate would have an anticipated saving of 70 million 
BEF (1.74 million Euro) over a two year period, for Belgium. Although this study provided a good 
estimate of the healthcare costs, there were some limitations. For instance, cost-benefits to the legal 
system or due to productivity losses were not determined. Also, the cost data were derived from the 
Belgian health care system, whereas the clinical data come from an Austrian study in which abstinence 
rates were considerably lower than other European studies [28]. 
In a study by Portella et al. [27] involving the total alcohol-dependent patient population in Spain 
(estimated to be approximately 627,400 people), it was calculated that treatment of AD (including 
hospitalization, physician visits, rehabilitation and medication) for the population would cost Spain  
Pta 42,430 million per year if 50% of AD patients received treatment (Pta 33,944 million if 40% 
received treatment and Pta 50,917 million if 60% received treatment). The total lifetime benefit for 
each rehabilitated patient, without any subsequent alcohol-related complications was calculated to be  
Pta 3,914,680 (23,528 €). The net benefit for the population if 50% of patients were treated under the  
best-case  scenario  (29.1%  of  treated  patients  become  rehabilitated,  25%  of  rehabilitated  patients 
develop  complications)  was  Pta  303,953  million,  and  under  the  worst  case  scenario  (10%  of  
treated  patients  become  rehabilitated,  75%  of  rehabilitated  patients  develop  complications)  was  
Pta 68,484 million. Varying the percentage of the patient population that would be treated between 40 
and 60% produced net benefit ranges between Pta 364,743 million for the best case scenario and  
Pta 54,87 million for the worst case scenario. 
This study has some limitations. While estimating the total lifetime benefit for each rehabilitated 
patient, it was assumed that there would be no subsequent alcohol-related complications. Again, most 
of  the  benefit  was  attributable  to  avoidance  of  indirect  costs  and  non-specific  direct  
costs (Pta 3,409,349), whereas direct health-related benefits were substantially less (Pta 05,331). Int. J. Environ. Res. Public Health 2011, 8                 
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4. Conclusions 
Treatment of alcoholism is associated with a decrease in total health care utilization [29,30] and 
thus, produces marked economic benefits for most of the treatment options. A present analysis of 
studies,  concerning  cost-benefit  attributable  to  AD  treatment,  revealed  that  most  of  the  treatment 
options produce marked economic benefits with the benefit-cost ratio ranging from 1.89 to 39.00. The 
highest benefit-cost ratios were observed in brief intervention studies [21,22]. 
All studies involving psychotherapy treatments have reported that major cost-benefits have been 
achieved in the first six months. The benefits to the healthcare system as well as the society as a whole, 
of course, continue to increase with time. While in most of the studies, individual counselling and 
behavioural  therapy  are  quite  effective  and  accrue  significant  economic  benefits,  some  treatment 
procedures like interactional couples therapy have resulted in negative benefit-cost ratios due to the 
high cost of treatment. In addition, it has to be noted that the participants in brief intervention studies 
included in this analysis [21-24] might not all be alcohol dependent but rather exhibit alcohol abuse. 
Although there are relatively more cost-benefit studies on psychotherapy treatments of AD, only 
two studies were identified that had included a CBA of pharmacotherapy for the treatment of AD. 
These two cost-benefit studies on pharmacotherapy of AD were related to acamprosate; there were no 
cost benefit study involving oral or injectable naltrexone, disulfiram or any other drug. Nonetheless, it 
is important to note from these few available studies that pharmacotherapy treatment of AD accrues 
economic benefits to the healthcare system as well as to society.  
It is important to note that the considerations for benefit-calculations have been different in the 
reviewed studies. While in some cases, the societal benefits included benefits to the health care system 
and the legal system; some other studies included savings in other indirect societal costs such as 
productivity losses. 
Reduction  of  binge  drinking/heavy  drinking  occasions  (both  regular  and  irregular)  and  its 
associated  problems  is  of  overriding  importance.  A  dichotomous  criterion  of  abstinence  does  not 
differentiate sufficiently, and is unrealistic, as many have a drink/relapse at one time or another. The 
reduction of heavy drinking occasions is a key for (a) health outcomes, and also for (b) criminality 
outcomes. The highest benefit in classical cost-benefit studies will, of course, be achieved if both 
dimensions are combined, and disability is included in the health outcomes. 
Studies on the economic aspects of AD treatment and psychiatric co-morbidity are scarce, although 
there are a number of studies that demonstrate the efficacy of pharmacotherapy of individuals with AD 
and  co-morbid  psychiatric  illness  [31].  However,  the  main  question  here  is  causality.  The  main 
problem is to identify the portion of co-morbidity, which is due to AD. Co-morbidity may be caused 
by AD, by the other condition, or by a third variable influencing both. We seem to have no way to 
disentangle  these  mechanisms.  One  way  to  deal  with  this  would  be  to  look  into  health  service 
utilization,  especially  in  mental  institutions,  before  and  after  pharmacotherapy  of  alcohol  
dependence - e.g., a design where service utilization is measured in the two years before and the two 
years after treatment and the costs are compared. 
The  vast  majority  of  identified  economic  analyses  were  cost  analyses,  often  mislabeled  as  
“cost-benefit analyses”. The reviewed studies usually compared the costs associated with treatment 
with  the  accompanying  (economic)  savings  and  estimated  net  costs  (or  savings).  However,  these Int. J. Environ. Res. Public Health 2011, 8                 
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studies commonly fail to estimate the indirect economic benefit of health effects (i.e., decreases in 
mortality and improvements in quality of life).  
Any new study on AD psychotherapy or pharmacotherapy should include a cost-benefit component. 
Cost-benefits should be evaluated with the inclusion of all major cost components. Other types of 
economic components that need to be included are cost-effectiveness (CE) and cost-utility (CU). In CE 
analysis, the incremental cost of a program from a particular viewpoint is related to the incremental 
health effects of the program measured in “natural units” such as a symptom score or symptom-free 
days. The results are expressed as cost per unit of effect in these units. CE components should be 
measured  with  the  key  outcomes  (i.e.,  amount  of  heavy  drinking  occasions).  In  CU  analysis,  
the  incremental  cost  of  a  program  from  a  particular  viewpoint  is  compared  to  the  incremental  
health  improvement  attributable  to  that  program,  where  the  health  improvement  is  measured  in  
quality-adjusted  life-years  (QALY)  gained.  Both  CE  and  CU  should  cover  a  longer  time  period  
(5–10 years), compared to the usual analyses of 6 to 12 months. A new study should thus include a 
short-term and a long-term component.  
Future economic evaluation studies should compare psychotherapy, pharmacotherapy or adjuvant 
treatments  involving  combined  medications.  There  is  also  a  need  for  an  intensive  study  of  the 
interactive effects of a number of combinations of medication other than naltrexone and acamprosate 
and psychosocial treatment [32]. 
Any new well-conducted economic study could help define the field further with respect to what 
should be the standard psychosocial treatment in addition to pharmacotherapy. Adjunctive psychosocial 
treatment with close follow-up is advisable for AD pharmacotherapy treatment [33]. The strengths of 
these  psychosocial  treatment  alternatives  to  enhance  medication  adherence,  preventing  attrition, 
addressing co-morbid problems, fostering abstinence, and targeting the weaknesses of the pharmacologic 
agent, as well as the characteristics of the target population need to be considered while choosing the 
type of psychosocial treatment [34]. 
Future studies also need to consider potential “side effects of treatment” (i.e., subjects may decrease 
their consumption of alcohol with a treatment, but increase their use of other substances). There is a 
need to examine the economic effects of AD treatment on other psychiatric disorders, especially if 
there are compounds that may have positive effects on both AD and psychiatric co-morbid disorders. 
Acknowledgments 
The  authors  wish  to  acknowledge  the  financial  assistance  for  this  study  from  Eli  Lilly  and 
Company, Indianapolis, USA. In addition, support to the Centre for Addiction and Mental Health for 
the salaries of scientists and infrastructure has been provided by the Ontario Ministry of Health and 
Long-Term  Care.  The  views  expressed  in  this  manuscript  do  not  necessarily  reflect  those  of  the 
Ontario Ministry of Health and Long-Term Care. Int. J. Environ. Res. Public Health 2011, 8                 
 
 
3362
References 
1.  Cunningham, J.A.; Blomquist, J. Examining treatment use among alcohol-dependent individuals 
from a population perspective. Alcohol Alcohol. 2006, 41, 632-635. 
2.  Humphreys, K.; Moos, R. Can encouraging substance abuse patients to participate in self-help 
groups  reduce demand  for health care? A Quasi-experimental study. Alcohol. Clin. Exp. Res. 
2001, 25, 711-716. 
3.  La Chance, H.; Feldstein, E.S.W.; Bryan, A.D.; Hutchison, K.E. What makes group motivational 
enhancement therapy (MET) work? A randomized controlled trial of college student drinkers in 
mandated alcohol diversion. Psychol. Addict. Behav. 2009, 23, 598-612. 
4.  Liddle, H.A.; Dakof, G.A.; Turner, R.M.; Henderson, C.E.; Greenbaum, P.E. Treating adolescent 
drug  abuse:  A  randomized  trial  comparing  multidimensional  family  therapy  and  cognitive 
behavior therapy. Addiction 2008, 103, 1660-1670. 
5.  Olive, M.F. Pharmacotherapies for alcoholism: The old and the new. CNS Neurol. Disord. Drug 
Targets 2010, 9, 2-4. 
6.  Williams, S.H. Medications for treating alcohol dependence. Am. Fam. Phys. 2005, 72, 1775-1780. 
7.  Anton, R.; O’Malley, S.; Ciraulo, D.; Cisler, R.; Couper, D.; Donovan, D.M.; Gastfriend, D.R.; 
Hosking, J.D.; Johnson, B.A.; LoCastro, J.S.; et al. Combined pharmacotherapies and behavioral 
interventions  for  alcohol  dependence.  The  COMBINE  study:  A  randomized  controlled  trial. 
JAMA 2006, 17, 2003-2017. 
8.  Bouza, C.; Angeles, M.; Munoz, A.; Amate, J.M. Efficacy and safety of naltrexone and acamprosate 
in the treatment of alcohol dependence: A systematic review. Addiction 2004, 99, 811-828. 
9.  Kranzler, H.R.; van Kirk, M. Efficacy of naltrexone and acamprosate for alcoholism treatment: A 
meta-analysis. Alcohol. Clin. Exp. Res. 2001, 25, 1335-1341. 
10.  Garbutt,  J.C.;  Kranzler,  H.R.;  O’Malley,  S.S.;  Gastriend,  D.R.;  Pettinati,  H.M.  Efficacy  and 
tolerability  of  long-acting  injectable  naltrexone  for  alcohol  dependence.  JAMA  2005,  293,  
1617-1625. 
11.  Mann,  K.;  Lehert,  P.;  Morgan,  M.Y.  The  efficacy  of  acamprosate  in  the  maintenance  of 
abstinence in alcohol-dependent individuals: Results of a meta-analysis. Alcohol. Clin. Exp. Res. 
2004, 28, 51-63. 
12.  Johnson, B.A.; Ait-Daoud, N.; Seneviratne, C.; Roache, J.D.; Javors, M.A.; Wang, X.Q.; Liu, L.; 
Penberthy,  J.K.;  DiClemente,  C.C.;  Li,  M.D.  Pharmacogenetic  approach  at  the  serotonin 
transporter gene as a method of reducing the severity of alcohol drinking. Am. J. Psychiatry 2011, 
168, 265-275. 
13.  Leggio, L.; Garbutt, J.C.; Addolorato, G. Effectiveness and safety of baclofen in the treatment of 
alcohol dependent patients. CNS Neurol. Disord. Drug Targets 2010, 9, 33-44. 
14.  Kranzler, H.R.; Armeli, S.; Tennen, H.; Covault, J.; Feinn, R.; Arias, A.J.; Pettinati, H.; Oncken, C. 
A double-blind, randomized trial of sertraline for alcohol dependence: Moderation by age and  
5-hydroxytryptamine  transporter-linked  promoter  region  genotype.  J.  Clin.  Psychopharmacol. 
2011, 31, 22-30. Int. J. Environ. Res. Public Health 2011, 8                 
 
 
3363
15.  Pettinati, H.M.; Oslin, D.W.; Kampman, K.M.; Dundon, W.D.; Xie, H.; Gallis, T.L.; Dackis, C.A.; 
O’Brien, C.P. A double-blind, placebo-controlled trial combining sertraline and naltrexone for 
treating co-occurring depression and alcohol dependence. Am. J. Psychiatry 2010, 167, 668-675. 
16.  Litten,  R.Z.;  Fertig,  J.; Mattson,  M.E.;  Egli,  M.  Development  of  medications  for  alcohol  use 
disorders:  Recent  advances  and  ongoing  challenges.  Expert  Opin.  Emerging  Drugs  2005,  10,  
323-343. 
17.  Kraemer,  K.L.  The  cost-effectiveness  and  cost-benefit  of  screening  and  brief  intervention  for 
unhealthy alcohol use in medical settings. Subst. Abus. 2007, 28, 67-77. 
18.  For Windows XP. Version 14. Minitab Inc.: State College, PA, USA, 2007. 
19.  O’Farrell, T.J.; Choquette, K.A.; Cutter, H.S.G.; Floyd, F.J.; Bayog, R.; Brown, E.D.; Lowe, J.; 
Chan, A.; Deneault, P. Cost-benefit and cost-effectiveness analyses of behavioral marital therapy 
as an addition to outpatient alcoholism treatment. J. Subst. Abus. 1996, 8, 145-166. 
20.  O’Farrell, T.J.; Choquette, K.A.; Cutter, H.S.G.; Brown, E.; Bayog, R.; McCourt, W.; Lowe, J.; 
Chan, A.; Deneault, P. Cost-benefit and cost-effectiveness analyses of behavioral marital therapy 
with or without relapse prevention sessions for alcoholics and their spouses. Behav. Ther. 1996, 
27, 7-24. 
21.  Fleming,  M.F.;  Mundt,  M.P.;  French,  M.T.;  Manwell,  L.B.;  Stauffacher,  E.A.;  Barry,  K.L. 
Benefit-cost analysis of brief physician advice with problem drinkers in primary care settings. 
Med. Care 2000, 38, 7-18. 
22.  Fleming,  M.F.;  Mundt,  M.P.;  French,  M.T.;  Manwell,  L.B.;  Stauffacher,  E.A.;  Barry,  K.L.  
Brief  Physician  advice  for  problem  drinkers:  Long  term  efficacy  and  benefit-cost  analysis. 
Alcohol. Clin. Exp. Res. 2002, 26, 36-43. 
23.  Mundt, M.P.; French, M.T.; Roebuck, M.C.; Manwell, L.B.; Barry, K.L. Brief physician advice 
for  problem  drinking  among  older  adults:  An  economic  analysis  of  cost  and  benefits.  
J. Stud. Alcohol. 2005, 66, 389-394. 
24.  Mundt, M.P. Analyzing the costs and benefits of brief intervention. Alcohol. Res. Health 2006, 
29, 34-36. 
25.  Gentilello, L.M.; Ebel, B.E.; Wickizer, T.M.; Salkever, D.S.; Rivara, F.P. Alcohol interventions 
for  trauma  patients  treated  in  emergency  departments  and  hospitals.  Ann.  Surg.  2005,  241,  
541-550. 
26.  Annemans,  L.;  Vanoverbeke,  N.;  Tecco,  J.;  D’Hooghe,  D.  Economic  evaluation  of  campral 
(acamprosate)  compared  to  placebo  in  maintaining  abstinence  in  alcohol-dependent  patients.  
Eur. Addict. Res. 2000, 6, 71-78. 
27.  Portella, E.; Ridao, M.; Carrillo, E; Ribas, E.; Ribó, C.; Salvat, M. Alcohol y su abuso: Impacto 
Socio Económico; Editorial Medica Panamericana, S.A.: Madrid, Spain, 1998. 
28.  Poldrugo,  F.;  Haeger,  D.A.;  Comte,  S.;  Walburg,  J.;  Palmer,  A.  A  critical  review  of 
pharmacoeconomic studies of acamprosate. Alcohol Alcohol. 2005, 40, 422-430. 
29.  Holder, H.D. Cost benefits of substance abuse treatment: An overview of results from alcohol and 
drug abuse. J. Ment. Health Policy Econ. 1998, 1, 23-29. 
30.  Kane, R.; Wall, M.; Potthoff, S.; Stromberg, K.; Dai, Y.; Meyer, Z. The effect of alcoholism 
treatment on medical care use. Med. Care 2004, 42, 395-402. Int. J. Environ. Res. Public Health 2011, 8                 
 
 
3364
31.  Swift, R.M. The pharmacotherapy of alcohol dependence: Clinical and economic aspects. Econ. 
Neurosci. 2001, 3, 62-66. 
32.  Kranzler,  H.R.  Pharmacotherapy  of  alcoholism:  Gaps  in  knowledge  and  opportunities  for 
research. Alcohol Alcohol. 2002, 35, 537-547. 
33.  Graham,  R.;  Wodak,  A.D.;  Whelan,  G.  New  pharmacotherapies  for  alcohol  dependence.  
Med. J. Aust. 2002, 177, 103-107. 
34.  Carroll,  K.M.;  Kosten,  T.R.;  Rounsaville,  B.J.  Choosing  a  behavioral  therapy  platform  for 
pharmacotherapy of substance users. Drug Alcohol Depend. 2004, 75, 123-134. 
©  2011  by  the  authors;  licensee  MDPI,  Basel,  Switzerland.  This  article  is  an  open  access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 